BLTE
Price
$155.94Alerts
Change
-$0.58 (-0.37%)
Updated
Nov 11 closing price
Capitalization
6.21B
One day until earnings call
Intraday BUY SELL Signals
PRAX
Price
$346.21Alerts
Change
+$8.62 (+2.55%)
Updated
Nov 11 closing price
Capitalization
7.75B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BLTE vs PRAX

BLTE vs PRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BLTE vs. PRAX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLTE is a Hold and PRAX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BLTE with price predictions
Nov 10, 2026

BLTE in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026

BLTE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 31 cases where BLTE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BLTE's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BLTE as a result. In 64 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for BLTE just turned positive on October 29, 2026. Looking at past instances where BLTE's MACD turned positive, the stock continued to rise in 30 of 36 cases over the following month. The odds of a continued upward trend are 83%.

Following a +10.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLTE advanced for three days, in 215 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for BLTE crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLTE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for BLTE entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.995) is normal, around the industry mean (3.498). P/E Ratio (-56.274) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. BLTE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLTE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PRAX with price predictions
Nov 10, 2026

Momentum Indicator for PRAX turns positive, indicating new upward trend

PRAX saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 89 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 41 of 43 cases over the following month. The odds of a continued upward trend are 90%.

PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +21.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 257 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PRAX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.498). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
PRAX: Fundamental Ratings
PRAX
OUTLOOK RATING
1..100
38
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
PROFIT vs RISK RATING
1..100
85
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
33
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BLTEPRAX
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
79%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BLTE: $156.52 vs. PRAX: $337.59)
Brand notoriety: BLTE and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BLTE: 113% vs. PRAX: 107%
Market capitalization -- BLTE: $6.21B vs. PRAX: $7.75B
BLTE [@Biotechnology] is valued at $6.21B. PRAX’s [@Biotechnology] market capitalization is $7.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BLTE’s FA Score shows that 1 FA rating(s) are green while PRAX’s FA Score has 2 green FA rating(s).

  • BLTE’s FA Score: 1 green, 4 red.
  • PRAX’s FA Score: 2 green, 3 red.
According to our system of comparison, both BLTE and PRAX are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLTE’s TA Score shows that 5 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s).

  • BLTE’s TA Score: 5 bullish, 4 bearish.
  • PRAX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BLTE is a better buy in the short-term than PRAX.

Price Growth

BLTE (@Biotechnology) experienced а +2.86% price change this week, while PRAX (@Biotechnology) price change was +20.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.

Reported Earning Dates

BLTE is expected to report earnings on Nov 12, 2026.

PRAX is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BLTE and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLTE has been loosely correlated with RAIN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BLTE jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
-0.74%
RAIN - BLTE
48%
Loosely correlated
-9.59%
TARS - BLTE
39%
Loosely correlated
+4.22%
VOR - BLTE
38%
Loosely correlated
-2.10%
MIST - BLTE
38%
Loosely correlated
-10.27%
PRAX - BLTE
36%
Loosely correlated
+1.39%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with FULC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
+1.39%
FULC - PRAX
45%
Loosely correlated
N/A
IMVT - PRAX
44%
Loosely correlated
+1.59%
LXEO - PRAX
43%
Loosely correlated
-2.55%
CGEM - PRAX
42%
Loosely correlated
-4.26%
CELC - PRAX
42%
Loosely correlated
-4.72%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLJJ34.030.35
+1.05%
AllianzIM U.S. Equity 6 Month Floor5 Jan/Jul ETF (FLJJ)
DFVE36.97-0.02
-0.06%
DoubleLine Fortune 500 Equal Weight ETF (DFVE)
TAIL10.07-0.08
-0.84%
Cambria Tail Risk ETF (TAIL)
JMBS43.19-0.42
-0.96%
Janus Henderson Mortgage-Backed Securities ETF (JMBS)
FFLG30.46-0.33
-1.07%
Fidelity Fundamental Large Cap Growth ETF (FFLG)